| Emerging strategies and agents to lower cardiovascular risk by increasing high density lipoprotein cholesterol levels. | |
| | |
MedLine Citation:
|
PMID: 19149567 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
For decades, the focus of therapy to mitigate cardiovascular risk has been to lower low density lipoprotein cholesterol (LDL-C), so called "bad cholesterol". Widespread use of statins has resulted in a large body of clinical experience, which indicates that lower LDL-C levels do indeed correlate with decreased risk of cardiovascular and coronary artery diseases (CVD and CAD). Given these findings, recommended targets for LDL-C levels are continually being revised lower. Interestingly, however, even at low LDL-C levels there remains a substantial residual risk of CVD and CAD, particularly in patients with additional contributing factors. Recent post-hoc analyses of several large lipid modulation trials specifically assessing high density lipoprotein cholesterol (HDL-C) have revealed that increased HDL-C levels confer additional benefit against risk of CVD and CAD, even when LDL-C levels are already low. Human clinical outcomes trials that specifically target increasing HDL-C have not yet been conducted. However, the strong epidemiological inverse correlation between HDL-C and CVD risk remains. Discovery efforts aimed at increasing circulating levels of HDL-C have increased dramatically in recent years. This review will cover recent efforts and agents being developed such as cholesterol ester transfer protein inhibitors and nicotinic acid receptor agonists among other potential strategies. |
| | |
Authors:
|
Scott Greenfeder |
Related Documents
:
|
221787 - Changes in lipoprotein composition during the menstrual cycle. 6956267 - Responses of serum lipoproteins to dietary cholesterol and type of fat in the baboon. 8677757 - Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymp... 6424427 - Influence of polyunsaturated and saturated fats on plasma lipids and lipoproteins in man. 1788147 - Calcitonin gene-related peptide in human obesity. 8754627 - Effect of protein supplemented cassava diet in rats. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current medicinal chemistry Volume: 16 ISSN: 0929-8673 ISO Abbreviation: Curr. Med. Chem. Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-01-19 Completed Date: 2009-03-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9440157 Medline TA: Curr Med Chem Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 144-56 Citation Subset: IM |
Affiliation:
|
Department of Cardiovascular and Metabolic Diseases, Schering-Plough Research Institute, USA. scott.greenfeder@spcorp.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
therapeutic use Antilipemic Agents / therapeutic use Cardiovascular Diseases / drug therapy* Cholesterol Ester Transfer Proteins / antagonists & inhibitors Cholesterol, HDL / blood, drug effects, metabolism* Cholesterol, LDL / blood, metabolism Coronary Artery Disease / drug therapy, etiology, prevention & control Humans Receptors, Cytoplasmic and Nuclear / agonists Receptors, G-Protein-Coupled / agonists Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Antilipemic Agents; 0/Cholesterol Ester Transfer Proteins; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Receptors, Cytoplasmic and Nuclear; 0/Receptors, G-Protein-Coupled |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeuti...
Next Document: Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders.